biotech
biotech Articles
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.
Published:
Last Updated:
Myovant Sciences has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
The SEC has charged the former senior director of regulatory affairs for Puma Biotechnology with insider trading ahead of the company’s news announcements about its drug to treat breast cancer.
Published:
Last Updated:
Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
Published:
Last Updated:
Alcobra saw its shares get halved on Thursday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on its late-stage trial.
Published:
Last Updated:
Shares of Genocea Biosciences saw a handy gain early on Thursday on positive news from its genital herpes trial, but investor enthusiasm was short lived.
Published:
Last Updated:
Intra-Cellular Therapies saw its shares absolutely crash on Thursday following the results from its late-stage schizophrenia trial.
Published:
Last Updated:
Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.
Published:
Last Updated:
In a Jefferies research report, the top growth stock picks for this week are littered with outstanding biotech companies that could be poised for some big moves.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Published:
Last Updated:
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
Published:
Last Updated:
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Published:
Last Updated:
The week of September 23 brought numerous analyst upgrades and downgrades in the biotech and biohealth space.
Published:
Last Updated:
Puma Biotechnology posted strong gains over the course of this past week, which began with some positive news from the FDA and continued with a huge analyst call.
Published:
Last Updated:
Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now shares are being...
Published:
Last Updated: